NASDAQ:CLSDClearside Biomedical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clearside Biomedical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.79 +0.03 (+1.70 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$1.72Now: $1.79▼$1.8050-Day Range$1.64MA: $1.84▼$2.0152-Week Range$0.56Now: $1.79▼$4.13Volume1.21 million shsAverage Volume233,348 shsMarket Capitalization$80.32 millionP/E RatioN/ADividend YieldN/ABeta0.96 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.75, Clearside Biomedical has a potential upside of 221.2% from its current price of $1.79.Amount of Analyst CoverageClearside Biomedical has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesClearside Biomedical has received 305 “outperform” votes. (Add your “outperform” vote.)Underperform VotesClearside Biomedical has received 257 “underperform” votes. (Add your “underperform” vote.)Community SentimentClearside Biomedical has received 54.27% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote “Outperform” if you believe CLSD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have sold 580.62% more of their company's stock than they have bought. Specifically, they have bought $9,400.00 in company stock and sold $63,978.00 in company stock.Percentage Held by InsidersOnly 13.10% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 25.62% of the stock of Clearside Biomedical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clearside Biomedical are expected to grow in the coming year, from ($0.44) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearside Biomedical has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSD Previous Symbol CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone678-270-3631Debt Debt-to-Equity Ratio0.08 Current Ratio1.71 Quick Ratio1.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.17 million Price / Sales37.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book7.16Profitability EPS (Most Recent Fiscal Year)($0.81) Net Income$-30,770,000.00 Net Margins-293.61% Return on Equity-165.19% Return on Assets-67.98%Miscellaneous Employees50 Outstanding Shares44,870,000Market Cap$80.32 million Next Earnings DateN/A OptionableOptionable $1.79 +0.03 (+1.70 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CLSD News and Ratings via Email Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions How has Clearside Biomedical's stock been impacted by COVID-19 (Coronavirus)? Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLSD stock has decreased by 30.9% and is now trading at $1.79. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Clearside Biomedical? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clearside Biomedical. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical Inc (NASDAQ:CLSD) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.13) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.13). Clearside Biomedical had a negative return on equity of 165.19% and a negative net margin of 293.61%. View Clearside Biomedical's earnings history. What price target have analysts set for CLSD? 6 brokers have issued 1-year price targets for Clearside Biomedical's shares. Their forecasts range from $4.00 to $8.00. On average, they expect Clearside Biomedical's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 221.2% from the stock's current price. View analysts' price targets for Clearside Biomedical. Has Clearside Biomedical been receiving favorable news coverage? News headlines about CLSD stock have trended positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clearside Biomedical earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about Clearside Biomedical. Are investors shorting Clearside Biomedical? Clearside Biomedical saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,660,000 shares, an increase of 5.7% from the July 15th total of 1,570,000 shares. Based on an average daily trading volume, of 395,900 shares, the short-interest ratio is currently 4.2 days. Currently, 5.0% of the company's shares are sold short. View Clearside Biomedical's Short Interest. Who are some of Clearside Biomedical's key competitors? Some companies that are related to Clearside Biomedical include Avadel Pharmaceuticals (AVDL), Aeglea Bio Therapeutics (AGLE), Immunic (IMUX), Osmotica Pharmaceuticals (OSMT), Concert Pharmaceuticals (CNCE), Affimed (AFMD), Selecta Biosciences (SELB), MEI Pharma (MEIP), MediciNova (MNOV), Bicycle Therapeutics (BCYC), Spero Therapeutics (SPRO), Menlo Therapeutics (MNLO), NextCure (NXTC), ProQR Therapeutics (PRQR) and Arbutus Biopharma (ABUS). View all competitors. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN) and Gran Tierra Energy (GTE). Who are Clearside Biomedical's key executives? Clearside Biomedical's management team includes the following people: Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)Mr. Charles A. Deignan, Chief Financial Officer (Age 55)Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)Mr. Rick McElheny, VP of Corp. Devel. When did Clearside Biomedical IPO? (CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. What is Clearside Biomedical's stock symbol? Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD." Who are Clearside Biomedical's major shareholders? Clearside Biomedical's stock is owned by many different institutional and retail investors. Top institutional investors include Principal Financial Group Inc. (0.08%), First Citizens Bank & Trust Co. (0.03%) and Virtu Financial LLC (0.03%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Clay Thorp, George M Lasezkay and Nancy J Hutson. View institutional ownership trends for Clearside Biomedical. Which institutional investors are buying Clearside Biomedical stock? CLSD stock was acquired by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., First Citizens Bank & Trust Co., and Virtu Financial LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Clay Thorp, George M Lasezkay, and Nancy J Hutson. View insider buying and selling activity for Clearside Biomedical. How do I buy shares of Clearside Biomedical? Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Clearside Biomedical's stock price today? One share of CLSD stock can currently be purchased for approximately $1.79. How big of a company is Clearside Biomedical? Clearside Biomedical has a market capitalization of $80.32 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe. What is Clearside Biomedical's official website? The official website for Clearside Biomedical is www.clearsidebio.com. How can I contact Clearside Biomedical? Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
